Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma

Jonas Busch; Christoph Seidel; Irena Goranova; Barbara Erber; Robert Peters; Frank Friedersdorff; Ahmed Magheli; Kurt Miller; Viktor Grünwald; Steffen Weikert

doi:10.1016/j.ejca.2013.10.017

Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma

Standard

Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. / Busch, Jonas; Seidel, Christoph; Goranova, Irena; Erber, Barbara; Peters, Robert; Friedersdorff, Frank; Magheli, Ahmed; Miller, Kurt; Grünwald, Viktor; Weikert, Steffen.

in: EUR J CANCER, Jahrgang 50, Nr. 3, 2014, S. 563-9.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Busch, J, Seidel, C, Goranova, I, Erber, B, Peters, R, Friedersdorff, F, Magheli, A, Miller, K, Grünwald, V & Weikert, S 2014, 'Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma', EUR J CANCER, Jg. 50, Nr. 3, S. 563-9. https://doi.org/10.1016/j.ejca.2013.10.017

APA

Busch, J., Seidel, C., Goranova, I., Erber, B., Peters, R., Friedersdorff, F., Magheli, A., Miller, K., Grünwald, V., & Weikert, S. (2014). Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. EUR J CANCER, 50(3), 563-9. https://doi.org/10.1016/j.ejca.2013.10.017

Vancouver

Busch J, Seidel C, Goranova I, Erber B, Peters R, Friedersdorff F et al. Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. EUR J CANCER. 2014;50(3):563-9. https://doi.org/10.1016/j.ejca.2013.10.017

Bibtex

@article{04e03d71387a4bd69d62a4b5ae8f2261,

title = "Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma",

abstract = "INTRODUCTION: Sequential use of targeted therapy (TT) has improved overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC). The value of objective response (OR) as compared to stable disease (SD) is unclear. We aimed to investigate OR of first-line TT and its impact on OS.MATERIAL AND METHODS: Retrospective analysis of OS among 331 mRCC patients with a first-line assessment according to RECIST 1.0. Characteristics between objective responders (complete response [CR] or partial remission [PR]), patients with SD and non-responders (progressive disease [PD] and toxicity [Tox]) were compared with the Chi-square test and the Kruskal-Wallis test. Kaplan-Meier analysis of OS and progression-free survival (PFS). Cox model analysis of Predictors of OS .RESULTS: Best response was CR, PR, SD, PD and Tox in 9 (2.7%), 61 (18.4%), 167 (50.5%), 80 (24.2%) and 14 (4.2%) patients respectively resulting in an OR rate of 21%. Median OS in months: CR 63.2; PR 37.6; SD 35.9; PD 14.6; TOX 22.5 (p<0.0001). Median PFS for responders was 14.8, 11.5 for patients with SD and 2.5 for non-responders (p<0.0001). Similarly median OS was 38.7, 35.9 and 15.5 (p<0.00001). Primary resistance and a first-line PFS <6months were the strongest independent predictors of OS. The achievement of OR as compared to SD did not impact OS.CONCLUSIONS: In our cohort of unselected patients OR was not associated with superior OS as compared to SD.",

author = "Jonas Busch and Christoph Seidel and Irena Goranova and Barbara Erber and Robert Peters and Frank Friedersdorff and Ahmed Magheli and Kurt Miller and Viktor Gr{\"u}nwald and Steffen Weikert",

year = "2014",

doi = "10.1016/j.ejca.2013.10.017",

language = "English",

volume = "50",

pages = "563--9",

journal = "EUR J CANCER",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "3",

}

RIS

TY - JOUR

T1 - Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma

AU - Busch, Jonas

AU - Seidel, Christoph

AU - Goranova, Irena

AU - Erber, Barbara

AU - Peters, Robert

AU - Friedersdorff, Frank

AU - Magheli, Ahmed

AU - Miller, Kurt

AU - Grünwald, Viktor

AU - Weikert, Steffen

PY - 2014

Y1 - 2014

N2 - INTRODUCTION: Sequential use of targeted therapy (TT) has improved overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC). The value of objective response (OR) as compared to stable disease (SD) is unclear. We aimed to investigate OR of first-line TT and its impact on OS.MATERIAL AND METHODS: Retrospective analysis of OS among 331 mRCC patients with a first-line assessment according to RECIST 1.0. Characteristics between objective responders (complete response [CR] or partial remission [PR]), patients with SD and non-responders (progressive disease [PD] and toxicity [Tox]) were compared with the Chi-square test and the Kruskal-Wallis test. Kaplan-Meier analysis of OS and progression-free survival (PFS). Cox model analysis of Predictors of OS .RESULTS: Best response was CR, PR, SD, PD and Tox in 9 (2.7%), 61 (18.4%), 167 (50.5%), 80 (24.2%) and 14 (4.2%) patients respectively resulting in an OR rate of 21%. Median OS in months: CR 63.2; PR 37.6; SD 35.9; PD 14.6; TOX 22.5 (p<0.0001). Median PFS for responders was 14.8, 11.5 for patients with SD and 2.5 for non-responders (p<0.0001). Similarly median OS was 38.7, 35.9 and 15.5 (p<0.00001). Primary resistance and a first-line PFS <6months were the strongest independent predictors of OS. The achievement of OR as compared to SD did not impact OS.CONCLUSIONS: In our cohort of unselected patients OR was not associated with superior OS as compared to SD.

AB - INTRODUCTION: Sequential use of targeted therapy (TT) has improved overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC). The value of objective response (OR) as compared to stable disease (SD) is unclear. We aimed to investigate OR of first-line TT and its impact on OS.MATERIAL AND METHODS: Retrospective analysis of OS among 331 mRCC patients with a first-line assessment according to RECIST 1.0. Characteristics between objective responders (complete response [CR] or partial remission [PR]), patients with SD and non-responders (progressive disease [PD] and toxicity [Tox]) were compared with the Chi-square test and the Kruskal-Wallis test. Kaplan-Meier analysis of OS and progression-free survival (PFS). Cox model analysis of Predictors of OS .RESULTS: Best response was CR, PR, SD, PD and Tox in 9 (2.7%), 61 (18.4%), 167 (50.5%), 80 (24.2%) and 14 (4.2%) patients respectively resulting in an OR rate of 21%. Median OS in months: CR 63.2; PR 37.6; SD 35.9; PD 14.6; TOX 22.5 (p<0.0001). Median PFS for responders was 14.8, 11.5 for patients with SD and 2.5 for non-responders (p<0.0001). Similarly median OS was 38.7, 35.9 and 15.5 (p<0.00001). Primary resistance and a first-line PFS <6months were the strongest independent predictors of OS. The achievement of OR as compared to SD did not impact OS.CONCLUSIONS: In our cohort of unselected patients OR was not associated with superior OS as compared to SD.

U2 - 10.1016/j.ejca.2013.10.017

DO - 10.1016/j.ejca.2013.10.017

M3 - SCORING: Journal article

C2 - 24239449

VL - 50

SP - 563

EP - 569

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

IS - 3

ER -